BACKGROUND: The CD4 T cell response to the tumor antigen Midkine was unknown. RESULTS: Most of the T cell response to Midkine relies on T cell epitopes contained in its signal peptide. CONCLUSION: The signal peptide of Midkine is accessible to HLA class II pathway for CD4 T cell presentation. SIGNIFICANCE: It is a new function for signal peptides to contribute to tumor-specific CD4 T cell response. Because of the key role of CD4 T cell response in immunity to tumors, we investigated the CD4(+) T cell response to the recently identified tumor antigen Midkine (MDK). By weekly stimulations of T lymphocytes harvested from seven HLA-DR-typed healthy donors, we derived CD4(+) T cell lines specific for eight MDK peptides. Most of the T cell lines reacted with the peptides 9-23 and 14-28, located in and overlapping the MDK signal peptide, respectively. Accordingly, the MDK signal peptide appeared to be rich in good binders to common HLA-DR molecules. The peptide 9-23-specific T cell lines were specifically stimulated by autologous dendritic cells loaded with lysates of MDK-transfected cells or with lysates of tumor cells naturally expressing the MDK protein. One T cell line was stimulated by HLA-compatible MDK-transfected tumor cells. By contrast, the peptide 14-28-specific T cell lines were not stimulated in any of these conditions. Our data demonstrate that CD4(+) T cell epitopes present in the signal peptide can be accessible to recognition by CD4(+) T cells and may therefore contribute to tumor immunity, whereas a peptide overlapping the junction between the signal peptide and the mature protein is not.
BACKGROUND: The CD4 T cell response to the tumor antigen Midkine was unknown. RESULTS: Most of the T cell response to Midkine relies on T cell epitopes contained in its signal peptide. CONCLUSION: The signal peptide of Midkine is accessible to HLA class II pathway for CD4 T cell presentation. SIGNIFICANCE: It is a new function for signal peptides to contribute to tumor-specific CD4 T cell response. Because of the key role of CD4 T cell response in immunity to tumors, we investigated the CD4(+) T cell response to the recently identified tumor antigen Midkine (MDK). By weekly stimulations of T lymphocytes harvested from seven HLA-DR-typed healthy donors, we derived CD4(+) T cell lines specific for eight MDK peptides. Most of the T cell lines reacted with the peptides 9-23 and 14-28, located in and overlapping the MDK signal peptide, respectively. Accordingly, the MDK signal peptide appeared to be rich in good binders to common HLA-DR molecules. The peptide 9-23-specific T cell lines were specifically stimulated by autologous dendritic cells loaded with lysates of MDK-transfected cells or with lysates of tumor cells naturally expressing the MDK protein. One T cell line was stimulated by HLA-compatible MDK-transfected tumor cells. By contrast, the peptide 14-28-specific T cell lines were not stimulated in any of these conditions. Our data demonstrate that CD4(+) T cell epitopes present in the signal peptide can be accessible to recognition by CD4(+) T cells and may therefore contribute to tumor immunity, whereas a peptide overlapping the junction between the signal peptide and the mature protein is not.
Entities:
Keywords:
Antigen Presentation; Epitope Mapping; Immunology; Major Histocompatibility Complex (MHC); T Cell; Tumor Immunology
Authors: Nejat K Egilmez; Stephen D Hess; Fang-An Chen; Hiroshi Takita; Thomas F Conway; Richard B Bankert Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701